ENFN Logo

Enfusion, Inc. (ENFN) Stock Forecast & Price Prediction

Live ENFN Stock Price & Analysis

Home Stocks United States | NYSE | Technology | Software - Application

$11.16

-0.06 (-0.53%)

12 Month Price Forecast For ENFN

$11.16
Current Price
$1.06B
Market Cap
6 Ratings
Buy 0
Hold 6
Sell 0
Wall St Analyst Ratings

Distance to ENFN Price Forecasts

+0.8%
To High Target of $11.25
+0.8%
To Median Target of $11.25
-13.6%
To Low Target of $9.64

ENFN Price Momentum

0.0%
1 Week Change
+8.5%
1 Month Change
+37.3%
1 Year Change
+8.3%
Year-to-Date Change
-1.9%
From 52W High of $11.38
+44.2%
From 52W Low of $7.74

🤔 Considering Enfusion (ENFN)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 8, 2025 3:09 AM UTC

ENFN Analyst Ratings & Price Targets

Based on our analysis of 10 Wall Street analysts, ENFN has a consensus that is neutral. The median price target is $11.25, with forecasts ranging from $9.64 to $11.25. Currently, there are 0 Buy ratings, 6 Hold ratings, and 0 Sell ratings.

With ENFN currently trading at $11.16, the median price forecast suggests a 0.8% upside. The most optimistic forecast comes from at , projecting a 0.8% upside, while at provides the most conservative target, suggesting a -13.6% downside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

ENFN Analyst Consensus

0
Buy
6
Hold
0
Sell

ENFN Price Target Range

Low
$9.64
Average
$11.25
High
$11.25
Current: $11.16

Latest ENFN Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for ENFN.

Date Firm Analyst Rating Change Price Target
Jan 13, 2025 William Blair Bhavan Suri Market Perform Downgrade $0.00
Dec 23, 2024 Piper Sandler Neutral Maintains $0.00
Dec 18, 2024 Stifel Buy Maintains $0.00
Mar 13, 2024 B of A Securities Koji Ikeda Underperform Maintains $9.00
Feb 28, 2024 Goldman Sachs Gabriela Borges Sell Downgrade $8.00
Jan 30, 2024 JP Morgan Alexei Gogolev Underweight Downgrade $9.00
Dec 20, 2023 Piper Sandler Sumeet Mody Neutral Maintains $10.00
Nov 7, 2023 UBS Kevin Mcveigh Neutral Initiates $9.00
Aug 9, 2023 Morgan Stanley James Faucette Overweight Maintains $11.00
Aug 9, 2023 Goldman Sachs Gabriela Borges Neutral Maintains $10.00
May 22, 2023 Piper Sandler Sumeet Mody Neutral Maintains $9.00
May 10, 2023 Credit Suisse Kevin Mcveigh Neutral Maintains $11.00
Apr 3, 2023 Piper Sandler Sumeet Mody Neutral Initiates $11.00
Mar 15, 2023 JP Morgan Alexei Gogolev Neutral Initiates $12.00
Jan 26, 2023 Goldman Sachs Gabriela Borges Neutral Maintains $9.50
Jan 4, 2023 B of A Securities Koji Ikeda Underperform Downgrade $10.00
Jan 3, 2023 Morgan Stanley James Faucette Overweight Upgrade $12.00
Oct 3, 2022 B of A Securities Koji Ikeda Neutral Downgrade $15.00
Aug 10, 2022 Morgan Stanley James Faucette Equal-Weight Maintains $13.00
Jul 14, 2022 Goldman Sachs Gabriela Borges Neutral Maintains $12.00

Stocks Similar to Enfusion, Inc.

The following stocks are similar to Enfusion based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Enfusion, Inc. (ENFN) Financial Data

Enfusion, Inc. has a market capitalization of $1.06B with a P/E ratio of 279.5x. The company generates $195.16M in trailing twelve-month revenue with a 1.7% profit margin.

Revenue growth is +15.4% quarter-over-quarter, while maintaining an operating margin of +5.8% and return on equity of +5.5%.

Valuation Metrics

Market Cap $1.06B
Enterprise Value $1.05B
P/E Ratio 279.5x
PEG Ratio 38.6x
Price/Sales 5.4x

Growth & Margins

Revenue Growth (YoY) +15.4%
Gross Margin +68.1%
Operating Margin +5.8%
Net Margin +1.7%
EPS Growth -22.6%

Financial Health

Cash/Price Ratio +4.6%
Current Ratio 3.6x
Debt/Equity 22.0x
ROE +5.5%
ROA +5.9%

🔥 Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Enfusion, Inc. logo

Enfusion, Inc. (ENFN) Company Overview

About Enfusion, Inc.

What They Do

Provides SaaS solutions for investment management.

Business Model

Enfusion, Inc. operates on a software-as-a-service (SaaS) model, offering a suite of solutions tailored for the investment management industry. The company generates revenue by providing its Portfolio Management System, Order and Execution Management System, and Accounting/General Ledger System, among other tools, which help financial professionals manage portfolios, execute trades, and comply with regulations.

Additional Information

Founded in 1997 and headquartered in Chicago, Illinois, Enfusion serves clients across the United States, Europe, the Middle East, Africa, and the Asia Pacific. Its services include technology-driven solutions and managed services, which enhance operational efficiency for investment firms.

Company Information

Sector

Technology

Industry

Software - Application

Employees

1,102

CEO

Mr. Oleg Movchan

Country

United States

IPO Year

2021

Enfusion, Inc. (ENFN) Latest News & Analysis

ENFN stock latest news image
Quick Summary

Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Enfusion, Inc. (NYSE:ENFN) and Clearwater Analytics. Investors are encouraged to seek more information on the firm's site.

Why It Matters

Merger investigations can signal potential risks or changes in a company's valuation, affecting stock performance and investor sentiment regarding Enfusion and Clearwater Analytics.

Source: Accesswire
Market Sentiment: Neutral
ENFN stock latest news image
Quick Summary

Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Enfusion, Inc. (NYSE:ENFN) and Clearwater Analytics, urging current investors to seek more information.

Why It Matters

The investigation into Enfusion's merger could signal potential legal or regulatory issues, impacting stock performance and investor sentiment toward Enfusion and Clearwater Analytics.

Source: Accesswire
Market Sentiment: Neutral
ENFN stock latest news image
Quick Summary

Bronstein, Gewirtz & Grossman is investigating Enfusion, Inc.'s merger with Clearwater Analytics. Investors holding Enfusion shares are encouraged to participate in the inquiry.

Why It Matters

The investigation into Enfusion's merger with Clearwater Analytics may impact stock performance and governance, affecting shareholder value and investment decisions.

Source: Accesswire
Market Sentiment: Neutral
ENFN stock latest news image
Quick Summary

Schall Law Firm is investigating potential fiduciary duty breaches by Enfusion, Inc. (NYSE:ENFN) directors and management, raising concerns for investors.

Why It Matters

The investigation into Enfusion's board for potential fiduciary breaches could lead to legal ramifications, affecting shareholder value and market perception.

Source: Accesswire
Market Sentiment: Neutral
ENFN stock latest news image
Quick Summary

The Schall Law Firm is investigating potential fiduciary duty breaches by the board of Enfusion, Inc. (NYSE:ENFN), which may impact shareholder interests.

Why It Matters

The investigation into Enfusion's board for potential fiduciary breaches could impact shareholder value and trust, influencing stock performance and investor sentiment.

Source: Accesswire
Market Sentiment: Neutral
ENFN stock latest news image
Quick Summary

Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Enfusion, Inc. (NYSE:ENFN) and Clearwater Analytics. Current investors are urged to seek more information.

Why It Matters

The investigation into the Enfusion-Clearwater merger may indicate potential legal or regulatory issues, impacting stock performance and investor confidence in Enfusion.

Source: Accesswire
Market Sentiment: Neutral

Frequently Asked Questions About ENFN Stock

What is Enfusion, Inc.'s (ENFN) stock forecast for 2025?

Based on our analysis of 10 Wall Street analysts, Enfusion, Inc. (ENFN) has a median price target of $11.25. The highest price target is $11.25 and the lowest is $9.64.

Is ENFN stock a good investment in 2025?

According to current analyst ratings, ENFN has 0 Buy ratings, 6 Hold ratings, and 0 Sell ratings. The stock is currently trading at $11.16. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for ENFN stock?

Wall Street analysts predict ENFN stock could reach $11.25 in the next 12 months. This represents a 0.8% increase from the current price of $11.16. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Enfusion, Inc.'s business model?

Enfusion, Inc. operates on a software-as-a-service (SaaS) model, offering a suite of solutions tailored for the investment management industry. The company generates revenue by providing its Portfolio Management System, Order and Execution Management System, and Accounting/General Ledger System, among other tools, which help financial professionals manage portfolios, execute trades, and comply with regulations.

What is the highest forecasted price for ENFN Enfusion, Inc.?

The highest price target for ENFN is $11.25 from at , which represents a 0.8% increase from the current price of $11.16.

What is the lowest forecasted price for ENFN Enfusion, Inc.?

The lowest price target for ENFN is $9.64 from at , which represents a -13.6% decrease from the current price of $11.16.

What is the overall ENFN consensus from analysts for Enfusion, Inc.?

The overall analyst consensus for ENFN is neutral. Out of 10 Wall Street analysts, 0 rate it as Buy, 6 as Hold, and 0 as Sell, with a median price target of $11.25.

How accurate are ENFN stock price projections?

Stock price projections, including those for Enfusion, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.